Immunomedics has received a patent for the production and use of peptide-based agents with bispecific antibodies or antibody fragments. The patent covers the use of the antibodies or fragments in "pretargeting" technology for imaging and treatment of various diseases. The technology also involves the use of molecular imaging methods, including SPECT and PET.

Full Story:
MSN Money

Related Summaries